Long-acting ocular drug delivery technologies with clinical precedent

References

• Lee VHL, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol Ther. 1986;2(1):67–108.
   Google Scholar
• Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol. 2000;27(7):558–562.
   PubMed Web of Science ®Google Scholar
• Rodrigues GA, Lutz D, Shen J, et al. Topical drug delivery to the posterior segment of the eye: addressing the challenge of preclinical to clinical translation. Pharm Res. 2018;35(12):245. DOI:10.1007/s11095-018-2519-x.
   PubMed Web of Science ®Google Scholar
• Taylor SRJ, Isa H, Joshi L, et al. New developments in corticosteroid therapy for Uveitis. Ophthalmologica. 2010;224(suppl 1):46–53. DOI:10.1159/000318021.
   PubMed Web of Science ®Google Scholar
• Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1(1):99–114.
   PubMedGoogle Scholar
• Subrizi A, Del Amo EM, Korzhikov-Vlakh V, et al., Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discov Today. 24(8): 1446–1457. 2019. DOI:10.1016/j.drudis.2019.02.001.
   PubMed Web of Science ®Google Scholar
• Yasukawa T, Ogura Y, Kimura H, et al. Drug delivery from ocular implants. Expert Opin Drug Deliv. 2006;3(2):261–273. DOI:10.1517/17425247.3.2.261.
   PubMedGoogle Scholar
• Cao Y, Samy KE, Bernards DA, et al. Recent advances in intraocular sustained-release drug delivery devices. Drug Discov Today. 2019;24(8):1694–1700. DOI:10.1016/j.drudis.2019.05.031.
   PubMed Web of Science ®Google Scholar
• Gote V, Sikder S, Sicotte J, et al. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370(3):602–624. DOI:10.1124/jpet.119.256933.
   PubMed Web of Science ®Google Scholar
• Pons-Faudoa FP, Ballerini A, Sakamoto J, et al. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomed Microdevices. 2019;21(2):47. DOI:10.1007/s10544-019-0389-6.
   PubMed Web of Science ®Google Scholar
• O’Brien MN, Jiang W, Wang Y, et al. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144–158.
   PubMed Web of Science ®Google Scholar
• García-Estrada P, García-Bon MA, López-Naranjo EJ, et al. Polymeric implants for the treatment of intraocular eye diseases: trends in biodegradable and non-biodegradable materials. Pharmaceutics. 2021;13(5):701. DOI:10.3390/pharmaceutics13050701.
   PubMed Web of Science ®Google Scholar
• Johnson AR, Forster SP, White D, et al. Drug eluting implants in pharmaceutical development and clinical practice. Expert Opin Drug Deliv. 2021;18(5):577–593. DOI:10.1080/17425247.2021.1856072.
   PubMed Web of Science ®Google Scholar
• Allyn MM, Luo RH, Hellwarth EB, et al. Considerations for polymers used in ocular drug delivery. Front Med (Lausanne). 2022;8 DOI:10.3389/fmed.2021.787644.• Outlines critical development considerations for use of polymers in Ocular LAIIs.
   PubMed Web of Science ®Google Scholar
• Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm. 2008;355(1):1–18.
   PubMedGoogle Scholar
• Başaran E, Yazan Y. Ocular application of chitosan. Expert Opin Drug Deliv. 2012;9(6):701–712.
   PubMed Web of Science ®Google Scholar
• Guvendiren M, Lu HD, Burdick JA. Shear-thinning hydrogels for biomedical applications. Soft Matter. 2012;8(2):260–272.
   Web of Science ®Google Scholar
• Jeong B, Kim SW, Bae YH. Thermosensitive sol–gel reversible hydrogels. Adv Drug Deliv Rev. 2012;64:154–162.
   Web of Science ®Google Scholar
• Yasin MN, Svirskis D, Seyfoddin A, et al. Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems. J Control Release. 2014;196:208–221.
   PubMed Web of Science ®Google Scholar
• Herlihy KP, Williams S, Owens G, et al. Extended release of microfabricated protein particles from biodegradable hydrogel implants for the treatment of age related macular degeneration. Invest Ophthalmol Vis Sci. 2014;55(13):1960.
   Web of Science ®Google Scholar
• Nguyen DD, Lai J-Y. Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment. Polym Chem. 2020;11(44):6988–7008.
   Web of Science ®Google Scholar
• Hashemi H, Khabazkhoob M, Mohazzab-Torabi S, et al. Anterior chamber angle and anterior chamber volume in a 40- to 64-year-old population. Eye Contact Lens. 2016;42(4):244–249. DOI:10.1097/ICL.0000000000000192.
   PubMed Web of Science ®Google Scholar
• Rabsilber TM, Khoramnia R, Auffarth GU. Anterior chamber measurements using pentacam rotating scheimpflug camera. J Cataract Refract Surg. 2006;32(3):456–459.
   PubMed Web of Science ®Google Scholar
• Goel M, Picciani RG, Lee RK, et al. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4(1):52–59. DOI:10.2174/1874364101004010052.
   PubMedGoogle Scholar
• Azhdam AM, Goldberg RA, Ugradar S. In vivo measurement of the human vitreous chamber volume using computed tomography imaging of 100 eyes. Trans Vision Sci Technol. 2020;9(1):2.
   PubMed Web of Science ®Google Scholar
• Chirila TV, Hong Y. Chapter C2 the vitreous humor. In: Murphy W, Black J, Hastings G, editors. Handbook of biomaterial properties. New York (NY): Springer; 2016. p. 125–134.
   Google Scholar
• Käsdorf Benjamin T, Arends F, Lieleg O. Diffusion regulation in the vitreous humor. Biophys J. 2015;109(10):2171–2181.
   PubMed Web of Science ®Google Scholar
• Liebmann JM, Barton K, Weinreb RN, et al. Evolving guidelines for intracameral injection. J Glaucoma. 2020;29:S1–S7.
   PubMed Web of Science ®Google Scholar
• Labetoulle M, Findl O, Malecaze F, et al. Evaluation of the efficacy and safety of a standardised intracameral combination of mydriatics and anaesthetics for cataract surgery. Br J Ophthalmol. 2016;100(7):976–985. DOI:10.1136/bjophthalmol-2015-307587.
   PubMed Web of Science ®Google Scholar
• Behndig A, Cochener B, Güell JL, et al. Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns in 9 European countries. J Cataract Refract Surg. 2013;39(9):1421–1431. DOI:10.1016/j.jcrs.2013.06.014.
   PubMed Web of Science ®Google Scholar
• Grzybowski A, Brona P, Zeman L, et al. Commonly used intracameral antibiotics for endophthalmitis prophylaxis: a literature review. Surv Ophthalmol. 2021;66(1):98–108. DOI:10.1016/j.survophthal.2020.04.006.
   PubMed Web of Science ®Google Scholar
• Keating GM. Intracameral cefuroxime. Drugs. 2013;73(2):179–186.
   PubMedGoogle Scholar
• Arshinoff SA, Modabber M. Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis. J Cataract Refract Surg. 2016;42(12):1730–1741.
   PubMed Web of Science ®Google Scholar
• Shorstein NH, Gardner S. Injection volume and intracameral moxifloxacin dose. J Cataract Refract Surg. 2019;45(10):1498–1502.
   PubMed Web of Science ®Google Scholar
• Yellepeddi VK, Sheshala R, McMillan H, et al. Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye. Drug Discov Today. 2015;20(7):884–889. DOI:10.1016/j.drudis.2015.01.013.
   PubMed Web of Science ®Google Scholar
• Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34(Supplement 12):S1–S18. DOI:10.1097/IAE.0000000000000399.
   PubMedGoogle Scholar
• Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravenous injections. Retina. 2004;24(5):S3–S19. DOI:10.1097/00006982-200410001-00002.
   PubMed Web of Science ®Google Scholar
• Guest J-M, Malbin B, Abrams G, et al. Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe. Int J Retin Vitr. 2022;8(1):27. DOI:10.1186/s40942-022-00375-3.
   PubMedGoogle Scholar
• Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review retina. Retina (Philadelphia, Pa.). 2004;24(5):676–698. DOI:10.1097/00006982-200410000-00002.
   PubMed Web of Science ®Google Scholar
• Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27(7):787–794.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. DOI:10.1136/bjophthalmol-2014-305327.
   PubMed Web of Science ®Google Scholar
• Kiss S, Dugel PU, Khanani AM, et al. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clinical ophthalmology. Vol. 12, Auckland (NZ): Dover Press; 2018. 1625–1635.
   Google Scholar
• Rao P, Lum F, Wood K, et al. Real-world vision in age-related macular degeneration patients treated with single antiVEGF drug type for 1 year in the IRIS registry. Ophthalmology. 2018;125(4):522–528. DOI:10.1016/j.ophtha.2017.10.010.
   PubMed Web of Science ®Google Scholar
• Khanani AM, Skelly A, Bezlyak V, et al. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmology Retina. 2020;4(2):122–133. DOI:10.1016/j.oret.2019.09.009.
   PubMedGoogle Scholar
• Rajesh B, Zarranz-Ventura J, Fung AT, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104(1):39–46. DOI:10.1136/bjophthalmol-2019-313991.
   PubMed Web of Science ®Google Scholar
• Kane FE, Burdan J, Cutino A, et al., Iluvien™: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv. 2008;5(9): 1039–1046. DOI:10.1517/17425247.5.9.1039. .
   PubMed Web of Science ®Google Scholar
• Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011;6(4):317–329.
   PubMedGoogle Scholar
• Gaudio P. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm. 2004;12(3):169–192.
   PubMed Web of Science ®Google Scholar
• de Carvalho Ra P, Krausse ML, Murphree AL, et al. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci. 2006;47(10):4532–4539. DOI:10.1167/iovs.06-0030.
   PubMed Web of Science ®Google Scholar
• Lima LH, Farah ME, Gum G, et al. Sustained and targeted episcleral delivery of celecoxib in a rabbit model of retinal and choroidal neovascularization. Int J Retin Vitr. 2018;4(1):31. DOI:10.1186/s40942-018-0131-1.
   PubMedGoogle Scholar
• Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med. 1997;337(2):83–90. DOI:10.1056/NEJM199707103370203.
   PubMed Web of Science ®Google Scholar
• Morlet N, Young S, Naidoo D, et al. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Br J Ophthalmol. 1996;80(3):214–216. DOI:10.1136/bjo.80.3.214.
   PubMed Web of Science ®Google Scholar
• Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol. 1994;112(12):1531–1539. DOI:10.1001/archopht.1994.01090240037023.
   PubMed Web of Science ®Google Scholar
• Marx JL, Kapusta MA, Patel SS, et al. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol. 1996;114(7):815–820. DOI:10.1001/archopht.1996.01100140029003.
   PubMedGoogle Scholar
• Schneider C, Langer R, Loveday D, et al. Applications of ethylene vinyl acetate copolymers (EVA) in drug delivery systems. J Control Release. 2017;262:284–295.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Ben-nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107(11):2024–2033. DOI:10.1016/S0161-6420(00)00466-8.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112(7):1192–1198.e1. DOI:10.1016/j.ophtha.2005.03.013.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–1027. DOI:10.1016/j.ophtha.2006.02.021.
   PubMed Web of Science ®Google Scholar
• Driot J-Y, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after retisert™ Intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther. 2004;20(3):269–275. DOI:10.1089/1080768041223611.
   PubMed Web of Science ®Google Scholar
• Stay MS, Xu J, Randolph TW, et al. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm Res. 2003;20(1):96–102. DOI:10.1023/A:1022207026982.
   PubMed Web of Science ®Google Scholar
• Friedrich S, Cheng Y-L, Saville B. Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Curr Eye Res. 1997;16(7):663–669.
   PubMed Web of Science ®Google Scholar
• Brumm MV, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device–a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55–64.
   PubMed Web of Science ®Google Scholar
• Chou K-J, Guo H, Ashton P, et al. Inventors; eyepoint pharmaceuticals, Inc, assignee. Injectable sustained release delivery devices. United States patent 8871241. 2014.
   Google Scholar
• Parrish RK, Campochiaro PA, Pearson PA, et al. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthalmic Surg Lasers Imaging. 2016;47(5):426–435. DOI:10.3928/23258160-20160419-05.
   Google Scholar
• Bailey C, Chakravarthy U, Lotery A, et al. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye. 2017;31(12):1707–1715. DOI:10.1038/eye.2017.125.
   PubMed Web of Science ®Google Scholar
• Eaton A, Koh SS, Jimenez J, et al. The USER study: a chart review of patients receiving a 0.2 µg/day fluocinolone acetonide implant for diabetic macular edema. Opthalmol Ther. 2019;8(1):51–62. DOI:10.1007/s40123-018-0155-5
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Lin P, Keenan RT, et al. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology. 2016;123(9):1940–1948. DOI:10.1016/j.ophtha.2016.05.025.
   PubMed Web of Science ®Google Scholar
• El-Ghrably IA, Saad A, Dinah C. A novel technique for repositioning of a migrated ILUVIEN® (Fluocinolone Acetonide) implant into the anterior chamber. Opthalmol Ther. 2015;4(2):129–133.DOI:10.1007/s40123-015-0035-1.
   PubMedGoogle Scholar
• Moisseiev E, Morse LS. Fluocinolone acetonide intravitreal implant in the visual axis. JAMA Ophthalmol. 2016;134(9):1067–1068.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019;126(8):1141–1154. DOI:10.1016/j.ophtha.2019.03.036.
   PubMed Web of Science ®Google Scholar
• Loewenstein A, Laganovska G, Bressler NM, et al. Phase 1 clinical study of the port delivery system with ranibizumab for continuous treatment of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2020;61(7):4201.
   Web of Science ®Google Scholar
• Campochiaro PA, Gune S, Maia M, et al. Pharmacokinetic (PK) profile of the port delivery system with ranibizumab (PDS) in the phase 2 ladder trial. Invest Ophthalmol Vis Sci. 2020;61(7):1157.
   Web of Science ®Google Scholar
• Khanani AM, Aziz AA, Weng CY, et al. Port delivery system: a novel drug delivery platform to treat retinal diseases. Expert Opin Drug Deliv. 2021;18(11):1571–1576. DOI:10.1080/17425247.2021.1968826.
   PubMed Web of Science ®Google Scholar
• Khanani AM, Callanan D, Dreyer R, et al. End-of-Study results for the ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2021;5(8):775–787. DOI:10.1016/j.oret.2020.11.004.
   PubMedGoogle Scholar
• Adamis AP, de Juan EJ. Development of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2022;33(3):131–136. DOI:10.1097/ICU.0000000000000851.
   PubMed Web of Science ®Google Scholar
• Yohe S, Maass KF, Horvath J, et al. In-vitro characterization of ranibizumab release from the port delivery system. J Control Release. 2022;345:101–107. DOI:10.1016/j.jconrel.2022.03.005.
   PubMed Web of Science ®Google Scholar
• Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2022;129(3):295–307. DOI:10.1016/j.ophtha.2021.09.016.
   PubMed Web of Science ®Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54(3):1616–1624. DOI:10.1167/iovs.12-10260.
   PubMed Web of Science ®Google Scholar
• Bantseev V, Schuetz C, Booler HS, et al. Evaluation of surgical factors affecting vitreous hemorrhage following port delivery system with Ranibizumab implant insertion in a minipig model. Retina. 2020;40(8):1520–1528. DOI:10.1097/IAE.0000000000002614.
   PubMed Web of Science ®Google Scholar
• Sharma A, Parachuri N, Kumar N, et al. The port delivery system with ranibizumab—journey of mitigating vitreous hemorrhage. Eye. 2022;36(3):488–489. DOI:10.1038/s41433-021-01830-5.
   PubMed Web of Science ®Google Scholar
• Fialho SL, Silva Cunha A. Manufacturing techniques of biodegradable implants intended for intraocular application. Drug Deliv. 2005;12(2):109–116.
   PubMed Web of Science ®Google Scholar
• Fredenberg S, Wahlgren M, Reslow M, et al., The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review. Int J Pharm. 2011;415(1):34–52. DOI:10.1016/j.ijpharm.2011.05.049.
   PubMedGoogle Scholar
• Lee SS, Hughes P, Ross AD, et al Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27(10):2043–2053. DOI:10.1007/s11095-010-0159-x.
   PubMed Web of Science ®Google Scholar
• Adrianto MF, Annuryanti F, Wilson CG, et al. In vitro dissolution testing models of ocular implants for posterior segment drug delivery. Drug Deliv Transl Res. 2022;12(6):1355–1375. DOI:10.1007/s13346-021-01043-z.
   PubMed Web of Science ®Google Scholar
• Zhang S, Nagapudi K, Shen M, et al. Release mechanisms and practical percolation threshold for long-acting biodegradable implants: an image to simulation study. J Pharm Sci. 2022;111(7): 1896–1910.
   PubMed Web of Science ®Google Scholar
• Awwad S, Day RM, Khaw PT, et al. Sustained release ophthalmic dexamethasone: in vitro in vivo correlations derived from the PK-Eye. Int J Pharm. 2017;522(1–2):119–127. DOI:10.1016/j.ijpharm.2017.02.047.
   PubMedGoogle Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309–317. DOI:10.1001/archopht.125.3.309.
   PubMed Web of Science ®Google Scholar
• Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147(6):1048–1054.e2. DOI:10.1016/j.ajo.2008.12.033.
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146.e3. DOI:10.1016/j.ophtha.2010.03.032.
   PubMed Web of Science ®Google Scholar
• Guigou S, Hajjar C, Parrat E, et al. Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study. J Fr Ophtalmol. 2014;37(6):480–485. DOI:10.1016/j.jfo.2014.03.001.
   PubMed Web of Science ®Google Scholar
• Chang-Lin J-E, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80–86. DOI:10.1167/iovs.10-5285.
   PubMed Web of Science ®Google Scholar
• Bhagat R, Zhang J, Farooq S, et al. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. J Ocul Pharmacol Ther. 2014;30(10):854–858. DOI:10.1089/jop.2014.0082.
   PubMed Web of Science ®Google Scholar
• Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex® implant. J Ophthalmic Inflamm Infect. 2012;2(1):1–5. DOI:10.1007/s12348-011-0042-x
   PubMedGoogle Scholar
• Lee DH, Chan CK. Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®). Am J Ophthalmol Case Rep. 2020;19:100725.
   PubMedGoogle Scholar
• Pardo-López D, Francés-Muñoz E, Gallego-Pinazo R, et al. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex). Graefe’s Arch Clin Exp Ophthalmol. 2012;250(11):1703. DOI:10.1007/s00417-011-1802-x.
   PubMed Web of Science ®Google Scholar
• Sirinek PE, Lin MM. Intracameral sustained release bimatoprost implants (Durysta). Semin Ophthalmol. 2022;37(3):385–390.
   PubMed Web of Science ®Google Scholar
• Shirley M. Bimatoprost Implant: first Approval. Drugs Aging. 2020;37(6):457–462.
   PubMed Web of Science ®Google Scholar
• Seal JR, Robinson MR, Burke J, et al. Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J Ocul Pharmacol Ther. 2019;35(1):50–57. DOI:10.1089/jop.2018.0067.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–1641. DOI:10.1016/j.ophtha.2020.06.018.
   PubMed Web of Science ®Google Scholar
• Ceonzo K, Gaynor A, Shaffer L, et al. Polyglycolic acid-induced inflammation: role of hydrolysis and resulting complement activation. Tissue Eng. 2006;12(2):301–308. DOI:10.1089/ten.2006.12.301.
   PubMedGoogle Scholar
• Thackaberry EA, Lorget F, Farman C, et al. The safety evaluation of long-acting ocular delivery systems. Drug Discov Today. 2019;24(8):1539–1550. DOI:10.1016/j.drudis.2019.05.032.
   PubMed Web of Science ®Google Scholar
• Mihov G, Draaisma G, Dias A, et al. Degradable polyesteramides: a novel platform for sustained drug delivery. J Control Release. 2010;148(1):e46–e47. DOI:10.1016/j.jconrel.2010.07.053.
   PubMed Web of Science ®Google Scholar
• Franken A, Kemp A, Messier K, et al. Degradable polyesteramides: a novel platform for ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 2011;52(14):3262.
   Google Scholar
• Glendenning A, Crews K, Sturdivant J, et al. Sustained release, biodegradable pea implants for intravitreal delivery of the ROCK/PKC inhibitor AR-13503. Invest Ophthalmol Vis Sci. 2018;59(9):5672.
   Web of Science ®Google Scholar
• Ding J, Crews K, Carbajal K, et al. Ocular tissue distribution and duration of release of AR-13503 following administration of AR-13503 sustained release intravitreal implant in rabbits and miniature swine. Invest Ophthalmol Vis Sci. 2019;60(9):5387.
   Web of Science ®Google Scholar
• Perry JL, Herlihy KP, Napier ME, et al. PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc Chem Res. 2011;44(10):990–998. DOI:10.1021/ar2000315.
   PubMed Web of Science ®Google Scholar
• DeSimone JM. Co-opting Moore’s law: therapeutics, vaccines and interfacially active particles manufactured via PRINT®. J Control Release. 2016;240:541–543.
   PubMed Web of Science ®Google Scholar
• Meng T, Kulkarni V, Simmers R, et al. Therapeutic implications of nanomedicine for ocular drug delivery. Drug Discov Today. 2019;24(8):1524–1538. DOI:10.1016/j.drudis.2019.05.006.
   PubMed Web of Science ®Google Scholar
• Navratil T, Garcia A, Tully J, et al. Preclinical evaluation of ENV515 (travoprost) intracameral implant - clinical candidate for treatment of glaucoma targeting six-month duration of action. Invest Ophthalmol Vis Sci. 2014;55(13):3548.
   Web of Science ®Google Scholar
• Navratil T, Garcia A, Verhoeven RS, et al. Advancing ENV515 (travoprost) intracameral implant into clinical development: nonclinical evaluation of ENV515 in support of first-time-in-human phase 2a clinical study. Invest Ophthalmol Vis Sci. 2015;56(7):5706. DOI:10.1167/iovs.14-16338.
   PubMedGoogle Scholar
• Pegoraro T, Tully J, Trevino L, et al. Evaluation of incorporation efficiency of dexamethasone in a polymer matrix for sustained release implant manufacturing. Invest Ophthalmol Vis Sci. 2019;60(9):3369.
   Web of Science ®Google Scholar
• Tully J, Williams S, Melton D, et al. AR-1105. Dexamethasone extended release and pharmacokinetics in the non-human primate. Invest Ophthalmol Vis Sci. 2018;59(9):5673.
   Web of Science ®Google Scholar
• Sulistio A, Mansfeld FM, Reyes-Ortega F, et al. Intra-articular treatment of osteoarthritis with diclofenac-conjugated polymer reduces inflammation and pain. ACS Appl Bio Mater. 2019;2(7):2822–2832. DOI:10.1021/acsabm.9b00232.
   PubMedGoogle Scholar
• O’Shea MS, Graichen FHM, Tait RJ, et al. inventors; PolyActiva Pty Ltd, assignee. Biodegradable polymer—bioactive moiety conjugates. United States patent US8535655B2. 2013.
   Google Scholar
• Battiston K, Parrag I, Statham M, et al. Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery. Nat Commun. 2021;12(1):2875. DOI:10.1038/s41467-021-23232-7.
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Parrag I, Louka D, et al. Pharmacokinetics and pharmacodynamics of a novel dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2019;60(9):1702.
   Web of Science ®Google Scholar
• Parrag I, Louka D, Fischer H, et al. Ocular pharmacokinetics, pharmacodynamics, and safety analysis of a novel dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2020;61(7):28.
   Web of Science ®Google Scholar
• Parrag IC, Statham MAJ, Battison K, et al. inventors; Ripple Therapeutics Corp, assignee. Dexamethasone prodrug compositions and uses thereof. United States patent US10588862B2. 2020.
   Google Scholar
• Yang M, Peterson WM, Yu Y, et al. GB-102 for wet AMD: a novel injectable formulation that safely delivers active levels of sunitinib to the retina and RPE/choroid for over four months. Invest Ophthalmol Vis Sci. 2016;57(12):5037.
   Web of Science ®Google Scholar
• Chang D, Park K, Famili A. Hydrogels for sustained delivery of biologics to the back of the eye. Drug Discov Today. 2019;24(8):1470–1482.
   PubMed Web of Science ®Google Scholar
• Lee A, Blair HA. Dexamethasone intracanalicular insert: a review in treating post-surgical ocular pain and inflammation. Drugs. 2020;80(11):1101–1108.
   PubMed Web of Science ®Google Scholar
• Tyson SL, Bafna S, Gira JP, et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019;45(2):204–212. DOI:10.1016/j.jcrs.2018.09.023.
   PubMed Web of Science ®Google Scholar
• Blizzard C, Desai A, Driscoll A. Pharmacokinetic studies of sustained-release depot of dexamethasone in beagle dogs. J Ocul Pharmacol Ther. 2016;32(9):595–600.
   PubMed Web of Science ®Google Scholar
• McGrath M, Blizzard CD, Desai A, et al. In vivo drug delivery of low solubility drugs from biodegradable hydrogel punctum plugs. Invest Ophthalmol Vis Sci. 2014;55(13):472.
   Web of Science ®Google Scholar
• Sawhney AS, Jarrett P, Bassett M, et al. inventors; Incept LLC, assignee. Drug delivery through hydrogel plugs. United States patent US8409606B2. 2013.
   Google Scholar
• Blizzard CD, Desai A, Driscoll A, et al. Ocular pharmacokinetics of OTX-DED, a sustained-release intracanalicular insert delivering dexamethasone, in a canine model. Invest Ophthalmol Vis Sci. 2021;62(8):1323.
   Web of Science ®Google Scholar
• Vanslette A, Haberman P, Blizzard CD, et al. Evaluating safety and pharmacokinetics of OTX-CSI, a sustained release intracanalicular cyclosporine insert in beagles. Invest Ophthalmol Vis Sci. 2020;61(7):3258.
   Web of Science ®Google Scholar
• Jarrett PK, Elhayek RF, Kahn E, et al. Efficacy & tolerability of OTX-TKI, a sustained hydrogel delivery system for a tyrosine kinase inhibitor, in a VEGF induced retinal leakage model: 1 year results. Invest Ophthalmol Vis Sci. 2019;60(9):372.
   Web of Science ®Google Scholar
• Wong JG, Chang A, Guymer RH, et al. Phase 1 study of an intravitreal axitinib hydrogel-based implant for the treatment of neovascular age-related macular degeneration (nAMD). Invest Ophthalmol Vis Sci. 2021;62(8):218.
   Google Scholar
• Jarrett T, Elhayek RF, Lattrell Z, et al. Pharmacokinetics of a 6 month sustained hydrogel delivery system for tyrosine kinase inhibitors in Dutch belted rabbits. Invest Ophthalmol Vis Sci. 2017;58(8):1984.
   Web of Science ®Google Scholar
• Blizzard CD, Desai A, Langh J, et al. Pharmacokinetics of OTX-TIC, a sustained release travoprost intracameral implant in rabbits. Invest Ophthalmol Vis Sci. 2019;60(9):3777.
   Web of Science ®Google Scholar
• Langh J, Blizzard CD, Driscoll A, et al. Effect of hydrogel persistence on pharmacodynamics and tolerability of OTX-TIC, travoprost intracameral implant in Beagles. Invest Ophthalmol Vis Sci. 2020;61(7):1242.
   Web of Science ®Google Scholar
• Blizzard CD, Desai A, D’Abbraccio S, et al. Efficacy and pharmacokinetics of a sustained release travoprost intracameral hydrogel implant in Beagle dogs. Invest Ophthalmol Vis Sci. 2018;59(9):1245.
   Web of Science ®Google Scholar
• Goldstein MH, Goldberg D, Walters TR, et al. Evaluating safety, tolerability and efficacy of an intracameral hydrogel-based travoprost implant in subjects with glaucoma - phase 1 trial. Invest Ophthalmol Vis Sci. 2020;61(7):4266.
   Web of Science ®Google Scholar